United States Pharmacovigilance Market Research Report 2023: Demand Soars for Pharmacovigilance in Response to Escalating Adverse Drug Reactions – Forecasts to 2028 – ResearchAndMarkets.com

United States Pharmacovigilance Market Research Report 2023: Demand Soars for Pharmacovigilance in Response to Escalating Adverse Drug Reactions – Forecasts to 2028 – ResearchAndMarkets.com

United States Pharmacovigilance Market Research Report 2023: Demand Soars for Pharmacovigilance in Response to Escalating Adverse Drug Reactions – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “United States Pharmacovigilance Market, By Region, Competition Forecast and Opportunities, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering.

The escalating incidence of Adverse Drug Reactions (ADRs) in the United States is anticipated to spur a significant surge in the demand for pharmacovigilance. ADRs, which refer to the harmful and unintended effects of medications, pose a considerable health risk to patients. These reactions can range from mild discomfort to severe complications that require hospitalization, prolonged illness, and in the worst cases, even death. The impact of ADRs goes beyond individual patients and extends to healthcare systems as well.

The financial burden imposed by the treatment and management of ADRs places additional strain on already stretched healthcare resources. Pharmacovigilance plays a crucial role in ensuring patient safety. It involves the systematic collection, detection, assessment, and prevention of drug-related problems.

By closely monitoring and evaluating the safety profile of medications, pharmacovigilance enables the early detection of ADRs. This timely identification facilitates the dissemination of updated drug safety information to healthcare providers and regulatory agencies. In turn, this can prompt necessary regulatory actions such as drug recalls or label changes to mitigate potential risks.

As the incidence of ADRs continues to rise, healthcare providers and regulatory agencies are increasingly recognizing the indispensability of robust pharmacovigilance systems. These systems not only serve as a means to detect and manage ADRs, but also enable the continuous monitoring and evaluation of medications post-market approval. By proactively monitoring the safety and efficacy of drugs, pharmacovigilance contributes to the overall improvement of patient care.

Consequently, the need to effectively manage, and ideally reduce, the incidence of ADRs is becoming more pressing. As a result, the demand for comprehensive, efficient, and proactive pharmacovigilance services is expected to rise significantly in the United States. This increased demand will necessitate the development and implementation of advanced pharmacovigilance strategies and technologies to ensure the safety and well-being of patients nationwide.

Key Market Trends

High Investment in Research & Development

Investment in Research and Development (R&D) is of paramount importance in bolstering the demand for pharmacovigilance in the United States. Notably, high R&D investment can lead to the development of new pharmaceutical products, requiring rigorous pharmacovigilance to ensure their effective and safe use. R&D initiatives often uncover complex drug interactions and side effects which further necessitate a robust system of pharmacovigilance to monitor, document, and manage.

Additionally, R&D investment drives innovation in pharmacovigilance methodologies themselves, such as automation and data analytics, which can enhance the efficiency and efficacy of pharmacovigilance systems. Increased technological capabilities can streamline the detection of adverse drug reactions, thereby fostering greater trust and demand for these services. Moreover, a well-funded R&D environment attracts more pharmaceutical companies to the market, contributing to an expanded need for pharmacovigilance. In essence, high R&D investment is integral to advancing the pharmacovigilance landscape by catalyzing innovation, improving safety measures, and ultimately, increasing the demand for pharmacovigilance in the United States.

Growth in the Pharmaceuticals & Biotechnology Sectors

The expected growth in the Pharmaceuticals & Biotechnology sectors in the United States is anticipated to significantly drive up the demand for Pharmacovigilance. This surge can be attributed to an increased focus on drug safety and efficacy, coupled with stricter federal regulations for drug approvals, post-marketing surveillance, and reporting of adverse drug reactions. The burgeoning growth of biotechnology firms and pharmaceutical companies also fuels the need for comprehensive pharmacovigilance to ensure patient safety and maintain public trust.

The development of groundbreaking biologics and medications necessitates meticulous monitoring to mitigate any potential risks and side effects. Furthermore, the sophistication of modern pharmaceuticals and biotechnology introduces a more complex risk landscape, thereby necessitating robust pharmacovigilance systems. Lastly, the rise of personalized medicine and biologics underpins the need for expanded pharmacovigilance activities, as these novel treatments often involve higher risks and require more stringent safety monitoring. Hence, the projected growth in both sectors will undoubtedly magnify the demand for pharmacovigilance in the United States.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Pharmacovigilance Market.

  • F. Hoffmann-La Roche & Co.
  • Laboratory Corporation of America Holdings
  • IBM Corporation
  • United BioSource Corporation
  • BioClinica Inc.
  • Novatis Corporation
  • ArisGlobal LLC
  • Cognizant Technology Solutions Corp
  • Accenture Inc.
  • Capgemini US LLCĀ 

Report Scope:

United States Pharmacovigilance Market, By Clinical Trial Phase:

  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

United States Pharmacovigilance Market, By Method:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

United States Pharmacovigilance Market, By Service Provider:

  • In-House
  • Contract Outsourcing

United States Pharmacovigilance Market, By End User:

  • Hospitals
  • Research Organizations
  • Industries

United States Pharmacovigilance Market, By Region:

  • Northeast Region
  • Midwest Region
  • West Region
  • South Region

For more information about this report visit https://www.researchandmarkets.com/r/qztfvk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.



Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900